Document is current
Any future updates will be listed below
-
Authors
Wills, Edward
Saji, Anjana https://orcid.org/0009-0007-0775-690X
Sumner, Jonathan
Khan, Aman https://orcid.org/0000-0003-2760-1490
Sisk, Claudia M. https://orcid.org/0009-0005-4294-0417
Shehata, Mona
Taylor, Benjamin https://orcid.org/0000-0001-6101-3786
Ladds, Graham https://orcid.org/0000-0001-7320-9612
-
Funding
Funding for this research was provided by:
RCUK | Biotechnology and Biological Sciences Research Council (BB/Y513817/1)
RCUK | Biotechnology and Biological Sciences Research Council (BB/W014831/1)
RCUK | Engineering and Physical Sciences Research Council (EP/X015785/1)
Takeda Pharmaceuticals U.S.A.
Royal Society (INF/R2/212001)
- License Information
-
More Information
Article History
Received: 12 May 2025
Accepted: 13 April 2026
First Online: 26 April 2026
Competing interests
: The authors JS, MS and BT declare the following competing interests: they are employees of, and shareholders in, AstraZeneca. The remaining authors declare no competing interests.
